Cohort studies of patients treated with metformin, insulin, or sulfonylureas reported mixed survival estimates that varied by drug and cancer type.2 Among newer GLDs, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been associated with improved survival compared with dipeptidyl peptidase-4 inhibitors (DPP4is).3 Although GLP-1RAs have been associated with a lower incidence of some cancers,4 their effect on survival remains unclear. The gene discussed is DPP4; the disease is cancer.